Sign in Subscribe

Archive

A collection of 715 issues

Latest

New ctDNA assay validated for minimal residual disease monitoring across solid tumors

Skip to content The CRC Digest ◇ RESEARCH New ctDNA assay validated for minimal residual disease monitoring across solid tumors The Haystack MRD assay, a tumor-informed ctDNA test that tracks patient-specific somatic mutations, has been analytically and clinically validated across 23 solid tumor types for detecting minimal residual disease at low

Prophylactic HIPEC analyzed for survival outcomes in locally advanced colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Prophylactic HIPEC analyzed for survival outcomes in locally advanced colorectal cancer A meta-analysis of 2,023 patients analyzed prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced colorectal cancer, extracting and pooling data to analyze peritoneal metastasis-free survival, disease-free survival, and overall survival.

ctDNA methylation profiling may predict prognosis beyond mutation testing

Skip to content The CRC Digest ◇ RESEARCH ctDNA methylation profiling may predict prognosis beyond mutation testing DNA methylation in circulating tumor DNA may provide additional prognostic information beyond mutation-based analysis by reflecting coordinated regulatory states associated with tumor behavior, including transcriptional programs and cellular plasticity. (Epigenomics) This content is informational

Inadequate bowel prep obscures polyps and early cancer signs, increases costs

Skip to content The CRC Digest ▪ SCREENING Inadequate bowel prep obscures polyps and early cancer signs, increases costs A new guideline emphasizes that inadequate bowel preparation can obscure polyps, lesions, or early signs of colorectal cancer while increasing procedure length and shortening surveillance intervals; experts recommend aiming for adequate prep

Immunotherapy combinations tested in pMMR/MSS rectal cancer

Skip to content The CRC Digest Immunotherapy combinations tested in pMMR/MSS rectal cancer Meta-analysis evaluates immune checkpoint inhibitor-based neoadjuvant therapy for proficient mismatch repair and microsatellite stable locally advanced rectal tumors. (Clinical Colorectal Cancer) This content is informational only and does not constitute medical advice. Always consult your oncologist

Study identifies risk factors for irinotecan liver toxicity

Skip to content The CRC Digest ♥ LIVING WITH CRC Study identifies risk factors for irinotecan liver toxicity A retrospective study of 229 cancer patients receiving irinotecan chemotherapy identified key risk factors for hepatotoxicity, which could help clinicians monitor and manage this side effect more effectively. (Frontiers in Oncology) This content

What helps survivors use their care plans after treatment

Skip to content The CRC Digest ♥ LIVING WITH CRC What helps survivors use their care plans after treatment Interviews with 30 breast and colorectal cancer survivors found that survivorship care plans were most helpful when survivors discussed them with their primary care providers and found the information reassuring and relevant

Selenium nanoparticles selectively target KRAS G13D mutation

Skip to content The CRC Digest ◇ RESEARCH Selenium nanoparticles selectively target KRAS G13D mutation Researchers developed selenium nanoparticles that specifically inhibit tumors driven by the KRAS G13D mutation—a variant that currently has no approved targeted therapies—by upregulating the tumor suppressor GPX2 and blocking metastasis pathways. (Advanced Science) This

Immune checkpoint inhibitors show promise in hard-to-treat rectal cancer subtype

Skip to content The CRC Digest ◆ TRIAL DATA Immune checkpoint inhibitors show promise in hard-to-treat rectal cancer subtype A new meta-analysis examined immune checkpoint inhibitor combinations as neoadjuvant therapy for locally advanced rectal cancer with proficient mismatch repair (pMMR) or microsatellite stable (MSS) tumors—a subtype that typically does not

CRC Research Update — August 20, 2026

Today's colorectal cancer research highlights